- Conditions
- Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
- Interventions
- ARV-393, Glofitamab
- Drug
- Lead sponsor
- Arvinas Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 329 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 10
- States / cities
- New Haven, Connecticut • Miami, Florida • Detroit, Michigan + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- HIV-1 Infection
- Interventions
- elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy
- Drug
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • San Diego, California • Torrance, California + 17 more
- Conditions
- Substance Abuse
- Interventions
- Meetings with implementation leader(s), the SAAS survey, Patient surveys
- Behavioral
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 113,123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • New York, New York
- Conditions
- Small Cell Lung Cancer
- Interventions
- NMS-03305293, Temozolomide
- Drug
- Lead sponsor
- Nerviano Medical Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Peoria, Illinois • Boston, Massachusetts • Nashville, Tennessee
- Conditions
- Esophageal Cancer, Gastric Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- cisplatin, edotecarin
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- epirubicin hydrochloride, panobinostat, gene expression analysis, protein expression analysis, western blotting, immunologic technique, laboratory biomarker analysis, pharmacological study
- Drug · Genetic · Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Chronic Pain, Schizophrenia, Psychotic Disorders, Bipolar Disorder, Affective Disorders, Psychotic
- Interventions
- Cognitive Behavioral Therapy for Chronic Pain (CBT-CP), Health & Wellness (H&W)
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma, Small Lymphocytic Lymphoma
- Interventions
- Pirtobrutinib, Venetoclax, Rituximab
- Drug
- Lead sponsor
- Loxo Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 803 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 31
- States / cities
- Scottsdale, Arizona • San Diego, California • San Francisco, California + 25 more
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Ofatumumab
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Maternal-Fetal Relations, Mother-Child Relations, Maternal Behavior
- Interventions
- Mindfulness-Based Childbirth and Parenting, Non-Mindfulness-Based Childbirth Class
- Behavioral
- Lead sponsor
- Heidemarie Laurent
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 95 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2024
- U.S. locations
- 2
- States / cities
- Champaign, Illinois • University Park, Pennsylvania
- Conditions
- Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- aldesleukin, filgrastim, sargramostim, busulfan, cyclophosphamide, melphalan, paclitaxel, thiotepa, bone marrow ablation with stem cell support, in vitro-treated peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 56 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2007
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Healthy Study Participants
- Interventions
- UCB0599, Esomeprazole, Placebo
- Drug · Other
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Chronic Stroke
- Interventions
- Active Vibrotactile coordinated reset, Sham vibrotactile coordinated reset
- Device
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v7, Stage III Rectal Cancer AJCC v7
- Interventions
- Bevacizumab, Capecitabine, Fluorouracil, Leucovorin Calcium, Oxaliplatin, Radiation Therapy, Therapeutic Conventional Surgery
- Biological · Drug · Radiation + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2019
- U.S. locations
- 107
- States / cities
- Birmingham, Alabama • New Britain, Connecticut • Atlanta, Georgia + 66 more
- Conditions
- Cardiac Toxicity, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Laboratory Biomarker Analysis, Questionnaires
- Other · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 597 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Hemiplegia
- Interventions
- m2 Bimanual Arm Trainer (BAT)
- Device
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Healthy Volunteers
- Interventions
- BIIB104, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Long Beach, California
- Conditions
- Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Hodgkin's Lymphoma
- Interventions
- Tacrolimus (ARM with Methotrexate), Tacrolimus (ARM with MMF and Cyclophosphamide), Methotrexate (ARM with Maraviroc), Methotrexate (ARM with Bortezomib), Maraviroc, Bortezomib, Mycophenolate mofetil, Cyclophosphamide
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 279 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 30
- States / cities
- Duarte, California • Stanford, California • Gainesville, Florida + 24 more
- Conditions
- Pleuritis, Non-specific
- Interventions
- Corticosteroid, No Corticosteroid
- Drug · Other
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- BMS-247550
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 23
- States / cities
- Duarte, California • Los Angeles, California • Sacramento, California + 15 more
- Conditions
- Stroke, Shoulder Pain
- Interventions
- Peripheral Nerve Stimulation, Physical Therapy, Sham-PT, Sham-PNS
- Device · Other
- Lead sponsor
- MetroHealth Medical Center
- Other
- Eligibility
- 21 Years to 89 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Charlotte, North Carolina • Cleveland, Ohio
- Conditions
- Complication of Prematurity, Immunologic Deficiency Syndromes
- Interventions
- Adjuvant, Blood Collection
- Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- Up to 55 Years
- Enrollment
- 142 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Stage I Uterine Sarcoma AJCC v7, Uterine Corpus Leiomyosarcoma
- Interventions
- Clinical Observation, Docetaxel, Doxorubicin Hydrochloride, Filgrastim, Gemcitabine Hydrochloride, Pegfilgrastim
- Other · Drug · Biological
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 608
- States / cities
- Huntsville, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 374 more
- Conditions
- Breast Cancer, Drug-induced Nausea and Vomiting
- Interventions
- acupressure therapy, management of therapy complications, nausea and vomiting therapy
- Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Houston, Texas